Search Within

Michael Morris

  1. "2006"
Formats
  1. Meeting Abstract (4)
  2. Journal Article (3)
Groups
  1. Department of Medicine (7)
  2. Genitourinary Oncology Service (7)
  3. Solid Tumor Oncology Division (7)
  4. Biostatistics Service (2)
  5. Epidemiology and Biostatistics (2)
  6. Hematologic Malignancies, Division of (2)

More Groups

People
  1. Howard Scher (4)
  2. Glenn Heller (2)
  3. Martin Fleisher (2)
  4. Susan Slovin (2)
  5. Tracy Smart-Curley (2)
  6. Andrew Wilton (1)

More People

Years
  1. 2006 (7)
Publications
  1. Journal of Clinical Oncology (3)
  2. Nature Clinical Practice Oncology (2)
  3. Clinical Cancer Research (1)
  4. EJC Supplements (1)
Publishers
  1. American Society of Clinical Oncology (3)
  2. Nature Publishing Group (2)
  3. American Association for Cancer Research (1)
  4. Pergamon-Elsevier Science Ltd (1)

Results (7)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I trial results of PCK3145 in patients (pts) with castrate metastatic prostate cancer (PC) - The US experience
    Meeting Abstract

    Slovin, S. F.; Daigneault, L.; Dulude, H.; Panchal, C.; Richardson, J.; Curley, T.; Delacruz, A.; Fleisher, M.; Morris, M.; Scher, H.
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save
  • Phase 2 trial of (177)Lutetium (Lu-177) radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody (mAb) J591 (Lu-177-J591) in patients (pts) with metastatic androgen-independent prostate cancer (AIPC)
    Meeting Abstract

    Morris, M. J.; Milowsky, M. I.; Pandit-Taskar, N.; Divgi, C.; David, K. A.; Rozario, C. P.; Vallabhajosula, S.; Goldsmith, S. J.; Scher, H. I.; Nanus, D. M.
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save
  • Correlative results of in-vivo monitoring of platelet-derived growth factor receptor (PDGFR) activation status in a randomized placebo-controlled trial of docetaxel +/- imatinib in castration-resistant prostate cancer (CRPC) and bone metastases (BM)
    Meeting Abstract

    Mathew, P.; Thall, P. F.; Wen, S.; Horne, E.; Johnson, M.; Oh, W. K.; Morris, M. J.; Logothetis, C. J.; Fidler, I. J.; Bucana, C.
    EJC Supplements (2006)

    Fulltext@MSK | Save
  • Preliminary results of a randomized placebo-controlled,double-blind trial of weekly docetaxel combined with imatinib in men with metastatic androgen-independent prostate cancer (AIPC) and bone metastases (BM)
    Meeting Abstract

    Mathew, P.; Thall, P. F.; Johnson, M. M.; Oh, W. K.; Meluch, A. A.; Morris, M. J.; Troncoso, P.; Bucana, C. D.; Fidler, I. J.; Logothetis, C. J.
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save
  • Paclitaxel and carboplatin versus mitoxantrone: Lessons of an underpowered study: Commentary
    Journal Article

    Morris, M. J.
    Nature Clinical Practice Oncology (2006)

    Fulltext@MSK | Save
  • Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials
    Journal Article

    Fleming, M. T.; Morris, M. J.; Heller, G.; Scher, H. I.
    Nature Clinical Practice Oncology (2006)

    Fulltext@MSK | Save
  • Rapid androgen cycling as treatment for patients with prostate cancer
    Journal Article

    Feltquate, D.; Nordquist, L.; Eicher, C.; Morris, M.; Smaletz, O.; Slovin, S.; Curley, T.; Wilton, A.; Fleisher, M.; Heller, G.; more...
    Clinical Cancer Research (2006)

    Fulltext@MSK | Save